サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：がんワクチン市場：2023-2033年
市場調査レポート
商品コード
1338830

がんワクチン市場：2023-2033年

Cancer Vaccines Market Report 2023-2033
出版日: | 発行: Visiongain Reports Ltd. | ページ情報: 英文 235 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=199.24円

ご注意:
Single UserとTeamライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

がんワクチン市場：2023-2033年
出版日: 2023年08月23日
発行: Visiongain Reports Ltd.
ページ情報: 英文 235 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがんワクチンの市場規模は2033年にかけて14%のCAGRで成長すると予測されています。

がんワクチン開発へのAIの導入が腫瘍学の分野に革命をもたらしています。AI主導の技術により、研究者は膨大な量の遺伝子・分子データを分析し、潜在的ながん抗原を特定し、ワクチンに最も適した標的を予測することができます。この合理化されたアプローチは、発見プロセスを加速させ、個々の患者に合わせた個別化がんワクチンを可能にします。さらに、AIアルゴリズムはワクチン製剤の最適化を支援し、その有効性と安全性プロファイルを向上させます。AIの力を活用することで、科学者たちは革新的ながんワクチンの開発と試験を迅速化し、がんとの闘いにおいてより効果的で的を絞った治療への新たな希望を提供することができます。

一方で、がんワクチンの製造工程は、厳しい規制ガイドラインやタイムラインの延長など、いくつかの課題に直面しています。これらの要因は、がんワクチンの開発、製造、商業化に大きな影響を与えます。

米国食品医薬品局 (FDA) や欧州医薬品庁 (EMA) などの規制機関は、ワクチンの安全性、有効性、品質を保証するために厳しい要件を課しています。広範な文書化、包括的な臨床試験データ、適正製造規範 (GMP) の遵守は、規制当局の承認を得るための前提条件です。

がんワクチンの製造工程は本質的に複雑で時間がかかるため、開発から商業化までの期間が長くなります。がんワクチンの開発には、安全性、有効性、免疫原性を確立するために何段階もの臨床試験を実施する必要があります。厳格な規制ガイドラインは、強固な試験デザイン、患者のリクルート、綿密なデータ収集と解析を要求します。このような大規模な臨床試験プロセスは、製造スケジュール全体を大幅に長引かせる可能性があります。

当レポートでは、世界のがんワクチンの市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 レポート概要

第2章 エグゼクティブサマリー

第3章 市場概要

  • 主な調査結果
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
  • COVID-19の影響分析
  • ポーターのファイブフォース分析
  • PEST分析

第4章 がんワクチン市場の分析：タイプ別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推計・予測
  • 予防ワクチン
  • 治療ワクチン

第5章 がんワクチン市場の分析：技術別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推計・予測
  • 樹状細胞
  • 組換え
  • 抗原/アジュバント
  • ウイルスベクター・DNA
  • 全細胞

第6章 がんワクチン市場の分析：適応症別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推計・予測
  • 子宮頸がん
  • 前立腺がん
  • その他

第7章 がんワクチン市場の分析：エンドユーザー別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推計・予測
  • 小児
  • 成人

第8章 がんワクチン市場の分析：地域別

  • 主要調査結果
  • 市場規模の推計・予測

第9章 北米のがんワクチン市場の分析

第10章 欧州のがんワクチン市場の分析

第11章 アジア太平洋のがんワクチン市場の分析

第12章 ラテンアメリカのがんワクチン市場の分析

第13章 中東・アフリカのがんワクチン市場の分析

第14章 企業プロファイル

  • 競合環境
  • 戦略的展望
  • GSK plc
  • Merck &Co., Inc.
  • Amgen Inc.
  • Walvax Biotechnology Co. Ltd.
  • OSE Immunotherapeutics
  • Synthaverse S. A. (Biomed-Lublin)
  • Dendreon Pharmaceuticals LLC
  • F. Hoffmann-La Roche Ltd
  • Moderna, Inc.
  • AstraZeneca

第15章 総論・提言

図表

List of Tables

  • Table 1 Cancer Vaccines Market Snapshot, 2023 & 2033 (US$ Million, CAGR %)
  • Table 2 Cancer Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 Cancer Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 Cancer Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
  • Table 5 Cancer Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
  • Table 6 Cancer Vaccines Market Forecast by Type, 2023-2033 (US$ Million, AGR%, CAGR %)
  • Table 7 Preventive Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR %)
  • Table 8 Therapeutic Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 9 Cancer Vaccines Market Forecast by Technology, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 10 Dendritic Cells Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 11 Recombinant Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 12 Antigen/Adjuvant Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 13 Viral Vector and DNA Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 14 Whole-cell Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 15 Cancer Vaccines Market Forecast by Indications, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 16 Cervical Cancer Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 17 Prostate Cancer Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 18 Other Indications Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 19 Cancer Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 20 Paediatrics Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 21 Adults Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 22 Cancer Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 23 North America Cancer Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 24 North America Cancer Vaccines Market Forecast by Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 25 North America Cancer Vaccines Market Forecast by Technology, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 26 North America Cancer Vaccines Market Forecast by Indications, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 27 North America Cancer Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 28 U.S. Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 29 Canada Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 30 Europe Cancer Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR %)
  • Table 31 Europe Cancer Vaccines Market Forecast by Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 32 Europe Cancer Vaccines Market Forecast by Technology, 2023-2033 (US$ Million, AGR%, CAGR %)
  • Table 33 Europe Cancer Vaccines Market Forecast by Indications, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 34 Europe Cancer Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 35 Germany Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 36 France Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 37 UK Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 38 Italy Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 39 Spain Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 40 Russia Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 41 Rest of Europe Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 42 Asia Pacific Cancer Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 43 Asia Pacific Cancer Vaccines Market Forecast by Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 44 Asia Pacific Cancer Vaccines Market Forecast by Technology, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 45 Asia Pacific Cancer Vaccines Market Forecast by Indications, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 46 Asia Pacific Cancer Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 47 Japan Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 48 China Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 49 India Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 50 Australia Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 51 South Korea Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 52 Rest of Asia Pacific Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR %)
  • Table 53 Latin America Cancer Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 54 Latin America Cancer Vaccines Market Forecast by Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 55 Latin America Cancer Vaccines Market Forecast by Technology, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 56 Latin America Cancer Vaccines Market Forecast by Indications, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 57 Latin America Cancer Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 58 Brazil Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 59 Mexico Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 60 Rest of Latin America Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 61 MEA Cancer Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 62 MEA Cancer Vaccines Market Forecast by Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 63 MEA Cancer Vaccines Market Forecast by Technology, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 64 MEA Cancer Vaccines Market Forecast by Indications, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 65 MEA Cancer Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 66 GCC Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 67 South Africa Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 68 Rest of MEA Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR %)
  • Table 69 Strategic Outlook
  • Table 70 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 71 GSK Plc: Product Benchmarking
  • Table 72 GSK Plc: Strategic Outlook
  • Table 73 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 74 Merck & Co., Inc.: Product Benchmarking
  • Table 75 Merck & Co., Inc.: Strategic Outlook
  • Table 76 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 77 Amgen Inc.: Product Benchmarking
  • Table 78 Amgen Inc.: Strategic Outlook
  • Table 79 Walvax Biotechnology Co. Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 80 Walvax Biotechnology Co. Ltd.: Product Benchmarking
  • Table 81 Walvax Biotechnology Co. Ltd.: Strategic Outlook
  • Table 82 OSE Immunotherapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 83 OSE Immunotherapeutic: Product Benchmarking
  • Table 84 OSE Immunotherapeutic: Strategic Outlook
  • Table 85 Synthaverse S. A. (Biomed-Lublin): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 86 Synthaverse S. A. (Biomed-Lublin): Product Benchmarking
  • Table 87 Dendreon Pharmaceuticals LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 Dendreon Pharmaceuticals LLC: Product Benchmarking
  • Table 89 Dendreon Pharmaceuticals LLC: Strategic Outlook
  • Table 90 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 F. Hoffmann-La Roche Ltd: Product Benchmarking
  • Table 92 F. Hoffmann-La Roche Ltd: Strategic Outlook
  • Table 93 Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 94 Moderna, Inc.: Product Benchmarking
  • Table 95 Moderna, Inc.: Strategic Outlook
  • Table 96 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 AstraZeneca: Product Benchmarking

List of Figures

  • Figure 1 Cancer Vaccines Market Segmentation
  • Figure 2 Cancer Vaccines Market by Type: Market Attractiveness Index
  • Figure 3 Cancer Vaccines Market by Technology: Market Attractiveness Index
  • Figure 4 Cancer Vaccines Market by Indications: Market Attractiveness Index
  • Figure 5 Cancer Vaccines Market by End-users: Market Attractiveness Index
  • Figure 6 Cancer Vaccines Market Attractiveness Index by Region
  • Figure 7 Cancer Vaccines Market Dynamics
  • Figure 8 Global Cancer Case Rate per 100,000 People, 2015-2020
  • Figure 9 Global Cancer Cases by Country, 2022
  • Figure 10 R&D Spending by Major Oncology Companies, 2018-2022
  • Figure 11 Cancer Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 12 Cancer Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 13 Cancer Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 14 Cancer Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 15 Cancer Vaccines Market: Porter's Five Forces Analysis
  • Figure 16 Cancer Vaccines Market: PEST Analysis
  • Figure 17 Cancer Vaccines Market by Type: Market Attractiveness Index
  • Figure 18 Cancer Vaccines Market Forecast by Type, 2023-2033 (US$ Million, AGR %)
  • Figure 19 Cancer Vaccines Market Share Forecast by Type, 2023, 2028, 2033 (%)
  • Figure 20 Preventive Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 21 Preventive Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 22 Therapeutic Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 23 Therapeutic Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 24 Cancer Vaccines Market by Technology: Market Attractiveness Index
  • Figure 25 Cancer Vaccines Market Forecast by Technology, 2023-2033 (US$ Million, AGR %)
  • Figure 26 Cancer Vaccines Market Share Forecast by Technology, 2023, 2028, 2033 (%)
  • Figure 27 Dendritic Cells Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 28 Dendritic Cells Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 29 Recombinant Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 30 Recombinant Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 31 Antigen/Adjuvant Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 32 Antigen/Adjuvant Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 33 Viral Vector and DNA Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 34 Viral Vector and DNA Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 35 Whole-cell Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 36 Whole-cell Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 37 Cancer Vaccines Market by Indications: Market Attractiveness Index
  • Figure 38 Cancer Vaccines Market Forecast by Indications, 2023-2033 (US$ Million, AGR %)
  • Figure 39 Cancer Vaccines Market Share Forecast by Indications, 2023, 2028, 2033 (%)
  • Figure 40 Cervical Cancer Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 41 Cervical Cancer Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 42 Prostate Cancer Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 43 Prostate Cancer Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 44 Other Indications Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 45 Other Indications Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 46 Cancer Vaccines Market by End-users: Market Attractiveness Index
  • Figure 47 Cancer Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 48 Cancer Vaccines Market Share Forecast by End-users, 2023, 2028, 2033 (%)
  • Figure 49 Paediatrics Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 50 Paediatrics Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 51 Adults Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 52 Adults Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 53 Cancer Vaccines Market Forecast by Region 2023 and 2033 (Revenue, CAGR%)
  • Figure 54 Cancer Vaccines Market Share Forecast by Region 2023, 2028, 2033 (%)
  • Figure 55 Cancer Vaccines Market by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 56 North America Cancer Vaccines Market Attractiveness Index
  • Figure 57 North America Cancer Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 58 North America Cancer Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 59 North America Cancer Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 60 North America Cancer Vaccines Market Forecast by Type, 2023-2033 (US$ Million, AGR %)
  • Figure 61 North America Cancer Vaccines Market Share Forecast by Type, 2023 & 2033 (%)
  • Figure 62 North America Cancer Vaccines Market Forecast by Technology, 2023-2033 (US$ Million, AGR %)
  • Figure 63 North America Cancer Vaccines Market Share Forecast by Technology, 2023 & 2033 (%)
  • Figure 64 North America Cancer Vaccines Market Forecast by Indications, 2023-2033 (US$ Million, AGR %)
  • Figure 65 North America Cancer Vaccines Market Share Forecast by Indications, 2023 & 2033 (%)
  • Figure 66 North America Cancer Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 67 North America Cancer Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 68 U.S. Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 69 Canada Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 70 Europe Cancer Vaccines Market Attractiveness Index
  • Figure 71 Europe Cancer Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 72 Europe Cancer Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 73 Europe Cancer Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 74 Europe Cancer Vaccines Market Forecast by Type, 2023-2033 (US$ Million, AGR %)
  • Figure 75 Europe Cancer Vaccines Market Share Forecast by Type, 2023 & 2033 (%)
  • Figure 76 Europe Cancer Vaccines Market Forecast by Technology, 2023-2033 (US$ Million, AGR %)
  • Figure 77 Europe Cancer Vaccines Market Share Forecast by Technology, 2023 & 2033 (%)
  • Figure 78 Europe Cancer Vaccines Market Forecast by Indications, 2023-2033 (US$ Million, AGR %)
  • Figure 79 Europe Cancer Vaccines Market Share Forecast by Indications, 2023 & 2033 (%)
  • Figure 80 Europe Cancer Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 81 Europe Cancer Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 82 Germany Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 83 France Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 84 UK Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 85 Italy Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 86 Spain Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 87 Russia Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 88 Rest of Europe Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 89 Asia Pacific Cancer Vaccines Market Attractiveness Index
  • Figure 90 Asia Pacific Cancer Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 91 Asia Pacific Cancer Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 92 Asia Pacific Cancer Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 93 Asia Pacific Cancer Vaccines Market Forecast by Type, 2023-2033 (US$ Million, AGR %)
  • Figure 94 Asia Pacific Cancer Vaccines Market Share Forecast by Type, 2023 & 2033 (%)
  • Figure 95 Asia Pacific Cancer Vaccines Market Forecast by Technology, 2023-2033 (US$ Million, AGR %)
  • Figure 96 Asia Pacific Cancer Vaccines Market Share Forecast by Technology, 2023 & 2033 (%)
  • Figure 97 Asia Pacific Cancer Vaccines Market Forecast by Indications, 2023-2033 (US$ Million, AGR %)
  • Figure 98 Asia Pacific Cancer Vaccines Market Share Forecast by Indications, 2023 & 2033 (%)
  • Figure 99 Asia Pacific Cancer Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 100 Asia Pacific Cancer Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 101 Japan Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 102 China Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 103 India Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 104 Australia Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 105 South Korea Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 106 Rest of Asia Pacific Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 107 Latin America Cancer Vaccines Market Attractiveness Index
  • Figure 108 Latin America Cancer Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 109 Latin America Cancer Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 110 Latin America Cancer Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 111 Latin America Cancer Vaccines Market Forecast by Type, 2023-2033 (US$ Million, AGR %)
  • Figure 112 Latin America Cancer Vaccines Market Share Forecast by Type, 2023 & 2033 (%)
  • Figure 113 Latin America Cancer Vaccines Market Forecast by Technology, 2023-2033 (US$ Million, AGR %)
  • Figure 114 Latin America Cancer Vaccines Market Share Forecast by Technology, 2023 & 2033 (%)
  • Figure 115 Latin America Cancer Vaccines Market Forecast by Indications, 2023-2033 (US$ Million, AGR %)
  • Figure 116 Latin America Cancer Vaccines Market Share Forecast by Indications, 2023 & 2033 (%)
  • Figure 117 Latin America Cancer Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 118 Latin America Cancer Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 119 Brazil Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 120 Mexico Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 121 Rest of Latin America Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 122 MEA Cancer Vaccines Market Attractiveness Index
  • Figure 123 MEA Cancer Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 124 MEA Cancer Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 125 MEA Cancer Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 126 MEA Cancer Vaccines Market Forecast by Type, 2023-2033 (US$ Million, AGR %)
  • Figure 127 MEA Cancer Vaccines Market Share Forecast by Type, 2023 & 2033 (%)
  • Figure 128 MEA Cancer Vaccines Market Forecast by Technology, 2023-2033 (US$ Million, AGR %)
  • Figure 129 MEA Cancer Vaccines Market Share Forecast by Technology, 2023 & 2033 (%)
  • Figure 130 MEA Cancer Vaccines Market Forecast by Indications, 2023-2033 (US$ Million, AGR %)
  • Figure 131 MEA Cancer Vaccines Market Share Forecast by Indications, 2023 & 2033 (%)
  • Figure 132 MEA Cancer Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 133 MEA Cancer Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 134 GCC Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 135 South Africa Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 136 Rest of MEA Cancer Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 137 GSK PLC: Net Revenue, 2017-2022 (US$ Billion, AGR%)
  • Figure 138 GSK PLC: R&D, 2017-2022 (US$ Billion, AGR%)
  • Figure 139 GSK Plc: Regional Market Shares, 2022
  • Figure 140 Merck & Co., Inc.: Net Revenue, 2017-2022 (US$ Billion, AGR%)
  • Figure 141 Merck & Co., Inc.: R&D, 2017-2022 (US$ Billion, AGR%)
  • Figure 142 Merck & Co., Inc.: Regional Market Shares, 2022
  • Figure 143 Amgen Inc.: Net Revenue, 2017-2022 (US$ Billion, AGR%)
  • Figure 144 Amgen Inc.: R&D, 2017-2022 (US$ Billion, AGR%)
  • Figure 145 Amgen Inc.: Regional Market Shares, 2022
  • Figure 146 Walvax Biotechnology Co. Ltd.: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 147 Walvax Biotechnology Co. Ltd.: R&D, 2018-2022 (US$ Million, AGR%)
  • Figure 148 OSE Immunotherapeutics: Net Revenue, 2018-2022 (US$ Million, AGR%)
  • Figure 149 OSE Immunotherapeutics: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 150 F. Hoffmann-La Roche Ltd: Net Revenue, 2018-2022 (US$ Billion, AGR%)
  • Figure 151 F. Hoffmann-La Roche Ltd: R&D, 2017-2022 (US$ Billion, AGR%)
  • Figure 152 Moderna, Inc.: Net Revenue, 2017-2022 (US$ Billion, AGR%)
  • Figure 153 Moderna, Inc.: R&D, 2017-2022 (US$ Billion, AGR%)
  • Figure 154 Moderna, Inc.: Regional Market Shares, 2022
  • Figure 155 AstraZeneca: Net Revenue, 2017-2022 (US$ Billion, AGR%)
  • Figure 156 AstraZeneca: R&D, 2017-2022 (US$ Billion, AGR%)
  • Figure 157 AstraZeneca: Regional Market Shares, 2022
目次
Product Code: PHA1277

The global Cancer Vaccines market is projected to grow at a CAGR of 14% by 2033.

“The Cancer Vaccines Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Adoption of Technology in Drug Development to Create Market Opportunities for Cancer Vaccines

The adoption of Artificial Intelligence (AI) in cancer vaccine development has revolutionized the field of oncology. AI-driven technologies enable researchers to analyze vast amounts of genetic and molecular data, identifying potential cancer antigens and predicting the most suitable targets for vaccines. This streamlined approach accelerates the discovery process and allows for personalized cancer vaccines tailored to individual patients. Additionally, AI algorithms aid in the optimization of vaccine formulations, enhancing their effectiveness and safety profiles. By harnessing the power of AI, scientists can expedite the development and testing of innovative cancer vaccines, providing new hope for more effective and targeted treatments in the fight against cancer. For instance, in terms of information and communication technologies, NEC Corporation has been in the forefront. It is currently steadily improving its decades-old artificial intelligence (AI) capabilities to quickly handle complex social concerns. The business is now using this acquired knowledge to tackle the problem of using AI to provide fully individualised medicines for cancer patients.

Stringent Regulatory Guidelines and Extended Timelines in the Manufacturing Process of Cancer Vaccines Likely to Challenge Industry Growth

The manufacturing process of cancer vaccines faces several challenges, including stringent regulatory guidelines and longer timelines. These factors significantly impact the development, production, and commercialization of cancer vaccines.

Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), impose rigorous requirements to ensure the safety, efficacy, and quality of vaccines. The extensive documentation, comprehensive clinical trial data, and adherence to Good Manufacturing Practices (GMP) are prerequisites for regulatory approval.

The manufacturing process of cancer vaccines is inherently complex and time-consuming, leading to extended timelines for their development and commercialization. Cancer vaccine development involves conducting multiple phases of clinical trials to establish safety, efficacy, and immunogenicity. The stringent regulatory guidelines demand robust trial design, patient recruitment, and meticulous data collection and analysis. This extensive clinical trial process can significantly prolong the overall manufacturing timeline.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the cancer vaccines market evolving?
  • What is driving and restraining the cancer vaccines market?
  • How will each cancer vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each cancer vaccines submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading cancer vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the cancer vaccines projects for these leading companies?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of cancer vaccines projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the cancer vaccines market?
  • Where is the cancer vaccines market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Cancer Vaccines Market today, and over the next 10 years:

  • Our 235-page report provides 97 tables and 157 charts/graphs exclusively to you
  • The report highlights key lucrative areas in the industry so you can target them - NOW
  • It contains in-depth analysis of global, regional and national sales and growth
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Cancer Vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
  • You will find original analyses, with business outlooks and developments
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Cancer Vaccines prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Type

  • Preventive Vaccines
  • Therapeutic Vaccines

Technology

  • Dendritic Cells
  • Recombinant
  • Antigen/Adjuvant
  • Viral Vector and DNA
  • Whole-cell

Indications

  • Cervical Cancer
  • Prostate Cancer
  • Other Indications

End-users

  • Paediatrics
  • Adults

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:

North America

  • U.S
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Russia
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Cancer Vaccines Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

  • Amgen Inc.
  • AstraZeneca
  • Dendreon Pharmaceuticals LLC
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • Merck & Co., Inc.
  • Moderna, Inc
  • OSE Immunotherapeutics
  • Synthaverse S.A. (Biomed-Lublin)
  • Walvax Biotechnology Co. Ltd.

Overall world revenue for Cancer Vaccines Market, 2023 to 2033 in terms of value the market will surpass US$8,060 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Cancer Vaccines Market, 2023 to 2033 report help you?

In summary, our 230+ page report provides you with the following knowledge:

  • Revenue forecasts to 2033 for Cancer Vaccines Market, 2023 to 2033 Market, with forecasts for type, technology, indications, and end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 21 key national markets - See forecasts for the Cancer Vaccines Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the Cancer Vaccines Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Cancer Vaccines Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Increasing Number of Cancer Cases to Drive the Vaccine Demand
      • 3.2.1.2 Rising investment by PPPs and Government to Boost the Market Growth
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Challenges Posed by Stringent Regulatory Guidelines and Extended Timelines in the Manufacturing Process of Cancer Vaccines
      • 3.2.2.2 Advancement in Personalised Medicine to Hamper the Market Growth
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Increasing Organic and Inorganic Activities to Boost the Cancer Vaccines Market Growth
      • 3.2.3.2 Adoption of Technology in Drug Development to Create Market Opportunities for Cancer Vaccines
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis

4 Cancer Vaccines Market Analysis by Type

  • 4.1 Key Findings
  • 4.2 Type Segment: Market Attractiveness Index
  • 4.3 Cancer Vaccines Market Size Estimation and Forecast by Type
  • 4.4 Preventive Vaccines
    • 4.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.4.2 Market Share by Region, 2023 & 2033 (%)
  • 4.5 Therapeutic Vaccines
    • 4.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 4.5.2 Market Share by Region, 2023 & 2033 (%)

5 Cancer Vaccines Market Analysis by Technology

  • 5.1 Key Findings
  • 5.2 Technology Segment: Market Attractiveness Index
  • 5.3 Cancer Vaccines Market Size Estimation and Forecast by Technology
  • 5.4 Dendritic Cells
    • 5.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.4.2 Market Share by Region, 2023 & 2033 (%)
  • 5.5 Recombinant
    • 5.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.5.2 Market Share by Region, 2023 & 2033 (%)
  • 5.6 Antigen/Adjuvant
    • 5.6.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.6.2 Market Share by Region, 2023 & 2033 (%)
  • 5.7 Viral Vector and DNA
    • 5.7.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.7.2 Market Share by Region, 2023 & 2033 (%)
  • 5.8 Whole-cell
    • 5.8.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.8.2 Market Share by Region, 2023 & 2033 (%)

6 Cancer Vaccines Market Analysis by Indications

  • 6.1 Key Findings
  • 6.2 Indications Segment: Market Attractiveness Index
  • 6.3 Cancer Vaccines Market Size Estimation and Forecast by Indications
  • 6.4 Cervical Cancer
    • 6.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.4.2 Market Share by Region, 2023 & 2033 (%)
  • 6.5 Prostate Cancer
    • 6.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.5.2 Market Share by Region, 2023 & 2033 (%)
  • 6.6 Other Indications
    • 6.6.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.6.2 Market Share by Region, 2023 & 2033 (%)

7 Cancer Vaccines Market Analysis by End-users

  • 7.1 Key Findings
  • 7.2 End-users Segment: Market Attractiveness Index
  • 7.3 Cancer Vaccines Market Size Estimation and Forecast by End-users
  • 7.4 Paediatrics
    • 7.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 7.4.2 Market Share by Region, 2023 & 2033 (%)
  • 7.5 Adults
    • 7.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 7.5.2 Market Share by Region, 2023 & 2033 (%)

8 Cancer Vaccines Market Analysis by Region

  • 8.1 Key Findings
  • 8.2 Regional Market Size Estimation and Forecast

9 North America Cancer Vaccines Market Analysis

  • 9.1 Key Findings
  • 9.2 North America Cancer Vaccines Market Attractiveness Index
  • 9.3 North America Cancer Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 9.4 North America Cancer Vaccines Market Size Estimation and Forecast by Country
  • 9.5 North America Cancer Vaccines Market Size Estimation and Forecast by Type
  • 9.6 North America Cancer Vaccines Market Size Estimation and Forecast by Technology
  • 9.7 North America Cancer Vaccines Market Size Estimation and Forecast by Indications
  • 9.8 North America Cancer Vaccines Market Size Estimation and Forecast by End-users
  • 9.9 U.S. Cancer Vaccines Market Analysis
  • 9.10 Canada Cancer Vaccines Market Analysis

10 Europe Cancer Vaccines Market Analysis

  • 10.1 Key Findings
  • 10.2 Europe Cancer Vaccines Market Attractiveness Index
  • 10.3 Europe Cancer Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 10.4 Europe Cancer Vaccines Market Size Estimation and Forecast by Country
  • 10.5 Europe Cancer Vaccines Market Size Estimation and Forecast by Type
  • 10.6 Europe Cancer Vaccines Market Size Estimation and Forecast by Technology
  • 10.7 Europe Cancer Vaccines Market Size Estimation and Forecast by Indications
  • 10.8 Europe Cancer Vaccines Market Size Estimation and Forecast by End-users
  • 10.9 Germany Cancer Vaccines Market Analysis
  • 10.10 France Cancer Vaccines Market Analysis
  • 10.11 UK Cancer Vaccines Market Analysis
  • 10.12 Italy Cancer Vaccines Market Analysis
  • 10.13 Spain Cancer Vaccines Market Analysis
  • 10.14 Russia Cancer Vaccines Market Analysis
  • 10.15 Rest of Europe Cancer Vaccines Market Analysis

11 Asia Pacific Cancer Vaccines Market Analysis

  • 11.1 Key Findings
  • 11.2 Asia Pacific Cancer Vaccines Market Attractiveness Index
  • 11.3 Asia Pacific Cancer Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 11.4 Asia Pacific Cancer Vaccines Market Size Estimation and Forecast by Country
  • 11.5 Asia Pacific Cancer Vaccines Market Size Estimation and Forecast by Type
  • 11.6 Asia Pacific Cancer Vaccines Market Size Estimation and Forecast by Technology
  • 11.7 Asia Pacific Cancer Vaccines Market Size Estimation and Forecast by Indications
  • 11.8 Asia Pacific Cancer Vaccines Market Size Estimation and Forecast by End-users
  • 11.9 Japan Cancer Vaccines Market Analysis
  • 11.10 China Cancer Vaccines Market Analysis
  • 11.11 India Cancer Vaccines Market Analysis
  • 11.12 Australia Cancer Vaccines Market Analysis
  • 11.13 South Korea Cancer Vaccines Market Analysis
  • 11.14 Rest of Asia Pacific Cancer Vaccines Market Analysis

12 Latin America Cancer Vaccines Market Analysis

  • 12.1 Key Findings
  • 12.2 Latin America Cancer Vaccines Market Attractiveness Index
  • 12.3 Latin America Cancer Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 12.4 Latin America Cancer Vaccines Market Size Estimation and Forecast by Country
  • 12.5 Latin America Cancer Vaccines Market Size Estimation and Forecast by Type
  • 12.6 Latin America Cancer Vaccines Market Size Estimation and Forecast by Technology
  • 12.7 Latin America Cancer Vaccines Market Size Estimation and Forecast by Indications
  • 12.8 Latin America Cancer Vaccines Market Size Estimation and Forecast by End-users
  • 12.9 Brazil Cancer Vaccines Market Analysis

12.10Mexico Cancer Vaccines Market Analysis

12.11Rest of Latin America Cancer Vaccines Market Analysis

13 MEA Cancer Vaccines Market Analysis

  • 13.1 Key Findings
  • 13.2 MEA Cancer Vaccines Market Attractiveness Index
  • 13.3 MEA Cancer Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 13.4 MEA Cancer Vaccines Market Size Estimation and Forecast by Country
  • 13.5 MEA Cancer Vaccines Market Size Estimation and Forecast by Type
  • 13.6 MEA Cancer Vaccines Market Size Estimation and Forecast by Technology
  • 13.7 MEA Cancer Vaccines Market Size Estimation and Forecast by Indications
  • 13.8 MEA Cancer Vaccines Market Size Estimation and Forecast by End-users
  • 13.9 GCC Cancer Vaccines Market Analysis
  • 13.10 South Africa Cancer Vaccines Market Analysis
  • 13.11 Rest of MEA Cancer Vaccines Market Analysis

14 Company Profiles

  • 14.1 Competitive Landscape, 2022
  • 14.2 Strategic Outlook
  • 14.3 GSK plc
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
      • 14.3.3.1 Net Revenue, 2017-2022
      • 14.3.3.2 R&D, 2017-2022
      • 14.3.3.3 Regional Market Shares, 2022
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 Merck & Co., Inc.
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
      • 14.4.3.1 Net Revenue, 2017-2022
      • 14.4.3.2 R&D, 2017-2022
      • 14.4.3.3 Regional Market Shares, 2022
    • 14.4.4 Product Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 Amgen Inc.
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
      • 14.5.3.1 Net Revenue, 2017-2022
      • 14.5.3.2 R&D, 2017-2022
      • 14.5.3.3 Regional Market Shares, 2022
    • 14.5.4 Product Benchmarking
    • 14.5.5 Strategic Outlook
  • 14.6 Walvax Biotechnology Co. Ltd.
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
      • 14.6.3.1 Net Revenue, 2018-2022
      • 14.6.3.2 R&D, 2018-2022
    • 14.6.4 Product Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 OSE Immunotherapeutics
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
      • 14.7.3.1 Net Revenue, 2018-2022
      • 14.7.3.2 R&D, 2017-2022
    • 14.7.4 Product Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.8 Synthaverse S. A. (Biomed-Lublin)
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Product Benchmarking
  • 14.9 Dendreon Pharmaceuticals LLC
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Product Benchmarking
    • 14.9.4 Strategic Outlook
  • 14.10 F. Hoffmann-La Roche Ltd
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
      • 14.10.3.1 Net Revenue, 2018-2022
      • 14.10.3.2 R&D, 2017-2022
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook
  • 14.11 Moderna, Inc.
    • 14.11.1 Company Snapshot
    • 14.11.2 Company Overview
    • 14.11.3 Financial Analysis
      • 14.11.3.1 Net Revenue, 2017-2022
      • 14.11.3.2 R&D, 2017-2022
      • 14.11.3.3 Regional Market Shares, 2022
    • 14.11.4 Product Benchmarking
    • 14.11.5 Strategic Outlook
  • 14.12 AstraZeneca
    • 14.12.1 Company Snapshot
    • 14.12.2 Company Overview
    • 14.12.3 Financial Analysis
      • 14.12.3.1 Net Revenue, 2017-2022
      • 14.12.3.2 R&D, 2017-2022
      • 14.12.3.3 Regional Market Shares, 2022
    • 14.12.4 Product Benchmarking

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from Visiongain
  • 15.2 Recommendations for Market Players